Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Prevnar, Sanofi-Aventis' ActHIB Vaccines Temporarily Suspended In Japan; Safety Committee Unwilling To Lift Action After First Meeting

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare temporarily suspended Pfizer Inc.'s Prevnar and Sanofi-Aventis SA's ActHIB following the death of four infants and now the companies find themselves in front of Japan's cautious safety council awaiting a decision that has the potential to have a large commercial impact, particularly on the blockbuster Prevnar, the latest iteration of which - Prevnar 13, a 13-valent vaccine for both children and adults - is currently in Phase III trials in Japan

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts